Related Experiment Video
Updated: May 16, 2026
09:00
High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
Published on: October 31, 2012
Are we making progress in GVHD prophylaxis and treatment?
Steven Z Pavletic1, Daniel H Fowler
1Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA. pavletis@mail.nih.gov
Hematology. American Society of Hematology. Education Program
|December 13, 2012
Summary
Allogeneic stem cell transplants (allo-HCT) are vital cancer immunotherapies. Despite advances reducing non-relapse mortality, graft-versus-host disease (GVHD) remains a significant challenge requiring new prevention and treatment strategies.
Area of Science:
- Hematology
- Immunotherapy
- Oncology
Background:
- Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a crucial immunotherapy for hematologic malignancies, with over 20,000 procedures annually worldwide.
- Technical innovations have halved non-relapse mortality (NRM) and improved survival in allo-HCT over the last two decades.
- Evolving practices include the use of peripheral blood, cord blood, haploidentical stem cells, and reduced-intensity conditioning, broadening the patient population treated.
Purpose of the Study:
- To review the current landscape of allogeneic hematopoietic stem cell transplantation (allo-HCT).
- To highlight persistent challenges, particularly graft-versus-host disease (GVHD), in the context of recent advancements.
- To discuss the future directions for GVHD prevention and therapy.
Main Methods:
- Review of current literature and clinical practices in allo-HCT.
- Analysis of trends in transplantation techniques and patient populations.
- Evaluation of the status of GVHD prevention and treatment strategies.
Main Results:
- Significant reductions in NRM (by 50%) and improvements in overall survival have been achieved through technical innovations in allo-HCT.
- Despite advancements, acute and chronic graft-versus-host disease (GVHD) remain major obstacles to successful allo-HCT outcomes.
- No single agent has yet received FDA approval for GVHD prevention or therapy, indicating an unmet clinical need.
Conclusions:
- While allo-HCT has seen substantial progress, GVHD continues to be a critical barrier requiring further research and development.
- Increased understanding of GVHD biology and clinical manifestations is paving the way for future breakthroughs.
- The ultimate goal is to develop therapies that effectively prevent or preempt life-threatening GVHD while preserving the beneficial graft-versus-tumor effect.
More Related Videos
08:04Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
06:06Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
Published on: May 23, 2019
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...